Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 5, Issue 2, 2013, Pages 163-179

  Xue, Shenghui ^a   Qiao, Jingjuan ^a   Pu, Fan ^a   Cameron, Mathew ^a   Yang, Jenny J ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AS-LIGANDS; BINDING AFFINITIES; CANCER BIOMARKERS; CLINICAL APPLICATION; DETECTION LIMITS; DISEASE BIOMARKER; DRUG ACTIVITIES; IN-VIVO; IN-VIVO IMAGING; MAGNETIC RESONANCE IMAGING (MRI); MAGNETIC RESONANCE IMAGING CONTRAST AGENTS; MRI CONTRAST AGENTS; PROTEIN RESIDUES; RELAXIVITY; TARGETING CAPABILITY; TUMOR BIOMARKERS;

BINDING ENERGY; DISEASES; DRUG THERAPY; GADOLINIUM; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; TUMORS; WIRE;

PROTEINS;

ALBUMIN; CHELATING AGENT; CONTRAST MEDIUM; DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GADOFOSVESET; GADOLINIUM; PENTETIC ACID; POLYAMIDOAMINE; PROTON; SCAFFOLD PROTEIN; TUMOR MARKER;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER DIAGNOSIS; COVALENT BOND; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; HUMANS; LIMIT OF DETECTION; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873735836     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1205     Document Type: Article

References (100)

1. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008, 452:580-589.
2. Caruthers SD, Winter PM, Wickline SA, Lanza GM. Targeted magnetic resonance imaging contrast agents. Methods Mol Med 2006, 124:387-400.
3. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004, 17:484-499.
4. Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging 2011, 29:587-600.
5. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002, 179:1193-1199.
6. Kim YR, Savellano MD, Weissleder R, Bogdanov A Jr. Steady-state and dynamic contrast MR imaging of human prostate cancer xenograft tumors: a comparative study. Technol Cancer Res Treat 2002, 1:489-495.
7. Raghunand N, Howison C, Sherry AD, Zhang S, Gillies RJ. Renal and systemic pH imaging by contrast-enhanced MRI. Magn Reson Med 2003, 49:249-257.
8. Wang Z, Su MY, Nalcioglu O. Applications of dynamic contrast enhanced MRI in oncology: measurement of tumor oxygen tension. Technol Cancer Res Treat 2002, 1:29-38.
9. Mueller GC, Hussain HK, Carlos RC, Nghiem HV, Francis IR. Effectiveness of MR imaging in characterizing small hepatic lesions: routine versus expert interpretation. AJR Am J Roentgenol 2003, 180:673-680.
10. Hu X, Norris DG. Advances in high-field magnetic resonance imaging. Annu Rev Biomed Eng 2004, 6:157-184.
11. Petiet AE, Kaufman MH, Goddeeris MM, Brandenburg J, Elmore SA, Johnson GA. High-resolution magnetic resonance histology of the embryonic and neonatal mouse: a 4D atlas and morphologic database. Proc Natl Acad Sci U S A 2008, 105:12331-12336.
12. Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 2009, 3:91-107.
13. Jones RA, Votaw JR, Salman K, Sharma P, Lurie C, Kalb B, Martin DR. Magnetic resonance imaging evaluation of renal structure and function related to disease: technical review of image acquisition, postprocessing, and mathematical modeling steps. J Magn Reson Imaging 2011, 33:1270-1283.
14. Major JL, Meade TJ. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res 2009, 42:893-903.
15. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev 2005, 57:2271-2286.
16. Atanasijevic T, Shusteff M, Fam P, Jasanoff A. Calcium-sensitive MRI contrast agents based on superparamagnetic iron oxide nanoparticles and calmodulin. Proc Natl Acad Sci U S A 2006, 103:14707-14712.
17. Yoo B, Pagel MD. A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc 2006, 128:14032-14033.
18. Shapiro MG, Westmeyer GG, Romero PA, Szablowski JO, Kuster B, Shah A, Otey CR, Langer R, Arnold FH, Jasanoff A. Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine. Nat Biotechnol 2010, 28:264-270.
19. Datta A, Raymond KN. Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res 2009, 42:938-947.
20. Geraldes CF, Laurent S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging 2009, 4:1-23.
21. Hanaoka K, Lubag AJ, Castillo-Muzquiz A, Kodadek T, Sherry AD. The detection limit of a Gd3+-based T1 agent is substantially reduced when targeted to a protein microdomain. Magn Reson Imaging 2008, 26:608-617.
22. Cheng Z, Thorek DL, Tsourkas A. Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl 2010, 49:346-350.
23. Gianolio E, Porto S, Napolitano R, Baroni S, Giovenzana GB, Aime S. Relaxometric investigations and MRI evaluation of a liposome-loaded pH-responsive gadolinium(III) complex. Inorg Chem 2012, 51: 7210-7217.
24. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280-1285.
25. Datta A, Hooker JM, Botta M, Francis MB, Aime S, Raymond KN. High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents. J Am Chem Soc 2008, 130:2546-2552.
26. Richard C, Doan BT, Beloeil JC, Bessodes M, Toth E, Scherman D. Noncovalent functionalization of carbon nanotubes with amphiphilic gd3+ chelates: toward powerful t1 and t2 MRI contrast agents. Nano Lett 2008, 8:232-236.
27. Caravan P, Greenwood JM, Welch JT, Franklin SJ. Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI contrast agents. Chem Commun (Camb) 2003:2574-2575.
28. Caravan P. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 2009, 42:851-862.
29. De Leon-Rodriguez LM, Lubag AJ, Malloy CR, Martinez GV, Gillies RJ, Sherry AD. Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res 2009, 42:948-957.
30. Viswanathan S, Kovacs Z, Green KN, Ratnakar SJ, Sherry AD. Alternatives to gadolinium-based metal chelates for magnetic resonance imaging. Chem Rev 2010, 110:2960-3018.
31. Terreno E, Castelli DD, Viale A, Aime S. Challenges for molecular magnetic resonance imaging. Chem Rev 2010, 110:3019-3042.
32. Li S, Jiang J, Zou J, Qiao J, Xue S, Wei L, Long R, Wang L, Castiblanco A, White N, et al. PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities. J Inorg Biochem 2012, 107:111-118.
33. Toth E, Helm L, Merbach AE. Relaxivity of MRI contrast agents. In: Krause W, ed. Contrast Agents: Magnetic Resonance Imaging, vol. 221. New York: Springer-Verlag; 2002, 61-102.
34. Solomon I. Relaxation processes in a system of two spins. Phys Rev 1955, 99:559-565.
35. Bloembergen N. Proton relaxation times in paramagnetic solutions. J Chem Phys 1957, 27:572-573.
36. Bloembergen N, Morgan R. Theory of proton relaxation by Mn2+ ions in solution. J Chem Phys 1961, 34:842.
37. McLachlan AD. Line widths of electron resonance spectra in solution. Proc R Soc Lond A 1964, 280:271-288.
38. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006, 35:512-523.
39. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006, 1:128-137.
40. Villaraza AJ, Bumb A, Brechbiel MW. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev 2010, 110:2921-2959.
41. Karfeld-Sulzer LS, Waters EA, Davis NE, Meade TJ, Barron AE. Multivalent protein polymer MRI contrast agents: controlling relaxivity via modulation of amino acid sequence. Biomacromolecules 2010, 11:1429-1436.
42. Wikstrom MG, Moseley ME, White DL, Dupon JW, Winkelhake JL, Kopplin J, Brasch RC. Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent. Invest Radiol 1989, 24:609-615.
43. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997, 7:68-74.
44. Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007, 46:6632-6639.
45. Bryant LH Jr, Brechbiel MW, Wu C, Bulte JW, Herynek V, Frank JA. Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates. J Magn Reson Imaging 1999, 9:348-352.
46. Helm L, Merbach AE. Inorganic and bioinorganic solvent exchange mechanisms. Chem Rev 2005, 105:1923-1959.
47. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999, 99:2293-2352.
48. Doble DM, Botta M, Wang J, Aime S, Barge A, Raymond KN. Optimization of the relaxivity of MRI contrast agents: effect of poly(ethylene glycol) chains on the water-exchange rates of Gd(III) complexes. J Am Chem Soc 2001, 123:10758-10759.
49. Caravan P, Greenfield MT, Li X, Sherry AD. The Gd(3+) complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities. Inorg Chem 2001, 40:6580-6587.
50. LaConte LE, Nitin N, Zurkiya O, Caruntu D, O'Connor CJ, Hu X, Bao G. Coating thickness of magnetic iron oxide nanoparticles affects R2 relaxivity. J Magn Reson Imaging 2007, 26:1634-1641.
51. Tong S, Hou S, Zheng Z, Zhou J, Bao G. Coating optimization of superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett 2010, 10:4607-4613.
52. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE, Fraser SE, Meade TJ. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000, 18:321-325.
53. Esqueda AC, Lopez JA, Andreu-de-Riquer G, Alvarado-Monzon JC, Ratnakar J, Lubag AJ, Sherry AD, De Leon-Rodriguez LM. A new gadolinium-based MRI zinc sensor. J Am Chem Soc 2009, 131:11387-11391.
54. Dhingra K, Maier ME, Beyerlein M, Angelovski G, Logothetis NK. Synthesis and characterization of a smart contrast agent sensitive to calcium. Chem Commun (Camb) 2008:3444-3446.
55. Li W-h, Fraser SE, Meade TJ. A calcium-sensitive magnetic resonance imaging contrast agent. J Am Chem Soc 1999, 121:1413-1414.
56. Pierre VC, Botta M, Aime S, Raymond KN. Tuning the coordination number of hydroxypyridonate-based gadolinium complexes: implications for MRI contrast agents. J Am Chem Soc 2006, 128:5344-5345.
57. Liepold L, Anderson S, Willits D, Oltrogge L, Frank JA, Douglas T, Young M. Viral capsids as MRI contrast agents. Magn Reson Med 2007, 58:871-879.
58. Yang W, Jones LM, Isley L, Ye Y, Lee HW, Wilkins A, Liu ZR, Hellinga HW, Malchow R, Ghazi M, et al. Rational design of a calcium-binding protein. J Am Chem Soc 2003, 125:6165-6171.
59. Yang W, Wilkins AL, Li S, Ye Y, Yang JJ. The effects of Ca2+ binding on the dynamic properties of a designed Ca2+-binding protein. Biochemistry 2005, 44:8267-8273.
60. Yang W, Wilkins AL, Ye Y, Liu ZR, Li SY, Urbauer JL, Hellinga HW, Kearney A, van der Merwe PA, Yang JJ. Design of a calcium-binding protein with desired structure in a cell adhesion molecule. J Am Chem Soc 2005, 127:2085-2093.
61. Maniccia AW, Yang W, Li SY, Johnson JA, Yang JJ. Using protein design to dissect the effect of charged residues on metal binding and protein stability. Biochemistry 2006, 45:5848-5856.
62. Li S, Yang W, Maniccia AW, Barrow D Jr, Tjong H, Zhou HX, Yang JJ. Rational design of a conformation-switchable Ca2+- and Tb3+-binding protein without the use of multiple coupled metal-binding sites. FEBS J 2008, 275:5048-5061.
63. Jones LM, Yang W, Maniccia AW, Harrison A, van der Merwe PA, Yang JJ. Rational design of a novel calcium-binding site adjacent to the ligand-binding site on CD2 increases its CD48 affinity. Protein Sci 2008, 17:439-449.
64. Yang JJ, Yang J, Wei L, Zurkiya O, Yang W, Li S, Zou J, Zhou Y, Maniccia AL, Mao H, et al. Rational design of protein-based MRI contrast agents. J Am Chem Soc 2008, 130:9260-9267.
65. Pidcock E, Moore GR. Structural characteristics of protein binding sites for calcium and lanthanide ions. J Biol Inorg Chem 2001, 6:479-489.
66. Kirberger M, Wang X, Zhao K, Tang S, Chen G, Yang JJ. Integration of diverse research methods to analyze and engineer Ca-binding proteins: from prediction to production. Curr Bioinform 2010, 5:68-80.
67. Kirberger M, Yang JJ. Structural differences between Pb2+- and Ca2+-binding sites in proteins: implications with respect to toxicity. J Inorg Biochem 2008, 102:1901-1909.
68. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006, 6:343-357.
69. Qiao J, Li S, Wei L, Jiang J, Long R, Mao H, Wang L, Yang H, Grossniklaus HE, Liu ZR, et al. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One 2011, 6:e18103.
70. Zhu W, Okollie B, Bhujwalla ZM, Artemov D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 2008, 59:679-685.
71. Wild JM, Woodrow J, van Beek EJ, Misselwitz B, Johnson R. Evaluation of rHA labeled with Gd-DTPA for blood pool imaging and targeted contrast delivery. Contrast Media Mol Imaging 2010, 5:39-43.
72. Schneider G, Pasowicz M, Vymazal J, Seidl Z, Aschauer M, Konopka M, Bilecen D, Iezzi R, Ballarati C. Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: multicenter intraindividual crossover comparison. AJR Am J Roentgenol 2010, 195:476-485.
73. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 2001, 12:128-134.
74. Kaneshiro TL, Jeong EK, Morrell G, Parker DL, Lu ZR. Synthesis and evaluation of globular Gd-DOTA-monoamide conjugates with precisely controlled nanosizes for magnetic resonance angiography. Biomacromolecules 2008, 9:2742-2748.
75. Alric C, Taleb J, Le Duc G, Mandon C, Billotey C, Le Meur-Herland A, Brochard T, Vocanson F, Janier M, Perriat P, et al. Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J Am Chem Soc 2008, 130:5908-5915.
76. Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, Koerner S, Kolodziej A, Shen L, Sun WC, et al. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl 2007, 46:8171-8173.
77. Polasek M, Fuchs BC, Uppal R, Schuhle DT, Alford JK, Loving GS, Yamada S, Wei L, Lauwers GY, Guimaraes AR, et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol 2012.
78. Spuentrup E, Ruhl KM, Botnar RM, Wiethoff AJ, Buhl A, Jacques V, Greenfield MT, Krombach GA, Gunther RW, Vangel MG, et al. Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model. Circulation 2009, 119:1768-1775.
79. Burtea C, Laurent S, Port M, Lancelot E, Ballet S, Rousseaux O, Toubeau G, Vander Elst L, Corot C, Muller RN. Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. J Med Chem 2009, 52:4725-4742.
80. De Leon-Rodriguez LM, Lubag A, Udugamasooriya DG, Proneth B, Brekken RA, Sun X, Kodadek T, Dean Sherry A. MRI detection of VEGFR2 in vivo using a low molecular weight peptoid-(Gd)8-dendron for targeting. J Am Chem Soc 2010, 132:12829-12831.
81. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, et al. Molecular MR imaging of melanoma angiogenesis with αvβ3-targeted paramagnetic nanoparticles. Magn Reson Med 2005, 53:621-627.
82. Boles KS, Schmieder AH, Koch AW, Carano RA, Wu Y, Caruthers SD, Tong RK, Stawicki S, Hu G, Scott MJ, et al. MR angiogenesis imaging with Robo4- vs. αVβ3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J 2010, 24:4262-4270.
83. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel α(v)β3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003, 63:5838-5843.
84. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with α(v)β3-integrin-targeted nanoparticles. Circulation 2003, 108:2270-2274.
85. Ouimet T, Lancelot E, Hyafil F, Rienzo M, Deux F, Lemaitre M, Duquesnoy S, Garot J, Roques BP, Michel JB, et al. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging. Mol Pharm 2012, 9:850-861.
86. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003, 63:2723-2727.
87. Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochem Pharmacol 2010, 80:731-738.
88. Allison M. The HER2 testing conundrum. Nat Biotechnol 2010, 28:117-119.
89. Orlova A, Magnusson M, Eriksson TL, Nilsson M, Larsson B, Hoiden-Guthenberg I, Widstrom C, Carlsson J, Tolmachev V, Stahl S, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006, 66:4339-4348.
90. Wei L, Li S, Yang J, Ye Y, Zou J, Wang L, Long R, Zurkiya O, Zhao T, Johnson J, et al. Protein-based MRI contrast agents for molecular imaging of prostate cancer. Mol Imaging Biol 2011, 13:416-423.
91. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009, 48:193-199.
92. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med 2008, 49:1735-1738.
93. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008, 60:1-42.
94. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001, 22:689-699.
95. Yoshimura T, Fujita K, Kawakami S, Takeda K, Chan S, Beligere G, Dowell B. Stability of pro-gastrin-releasing peptide in serum versus plasma. Tumour Biol 2008, 29:224-230.
96. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 2008, 29: 1912-1919.
97. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nat Biotechnol 2007, 25:1165-1170.
98. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
99. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
100. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006, 98:335-344.